相关实验视频

Updated: Jul 4, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

比PD-L1更显著地与TSCC的不良预后相关的是HHLA2

Yi Li¹, Qiong Yang¹, Xu Yang¹

¹Department of Oral and Maxillofacial Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology

|February 6, 2024

概括

HHLA2是舌头状细胞癌的有前途的免疫治疗标,表现出比PD-L1.1更高的表达和预后影响. 这一发现为患有这种侵袭性癌症的患者提供了新的希望.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

舌头状细胞癌的发病率和死亡率正在上升.
与PD-L1相比,研究HHLA2作为潜在的免疫检查点至关重要.

研究的目的:

为了比较HHLA2和PD-L1作为舌头状细胞癌的免疫检查点的疗效.
评估HHLA2的预后值和相关的分子通路.

主要方法:

对RNA-seq和单细胞RNA-seq数据分析 (TCGA,GEO).
对于HHLA2和PD-L1表达的免疫组织化学.
使用卡普兰-梅尔和考克斯回归的预后分析.
细胞类型丰度估计通过CIBERSORT.

主要成果:

在瘤和正常组织中,HHLA2和PD-L1表达显著上调.
HHLA2 (36.9%) 的阳性表达高于PD-L1 (24.6%).
HHLA2是舌头状细胞癌的整体存活率的独立风险因素.

结论:

在舌头状细胞癌中,HHLA2显示出作为优越免疫治疗点的潜力,超过PD-L1.
HHLA2与细胞循环调节和干扰素信号通路有关.

关键词:

这就是HHLA2的含量.在PD-L1中.在 TSCC 中,TSCC 已成为 TSCC 的核心.免疫疗法免疫疗法预后预后预后

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...